晚期食道癌在临床应用中靶向药物治疗的研究进展
摘要
关键词
全文:
PDF镜像
|参考
[1]Yang H, Li X, Yang W. Advances in targeted therapy and immunotherapy for esophagealcancer. Chin Med J (Engl). 2023;136(16):1910-1922. doi:10.1097/CM9.0000000000002768
[2]Rosario R, Cui W, Anderson RA. Potential ovarian toxicity and infertility risk following targeted anti-cancer therapies. Reprod Fertil 2022;3:R147-R162. doi: 10.1530/RAF-22-0020.
[3]Gao Y, Shen JK, Milane L, Hornicek FJ, Amiji MM, Duan Z. Targeted cancer therapy; nanotechnology approaches for over coming drug resistance. Curr Med Chem 2015;22:1335–1347. doi: 10.2174/0929867322666150209151851.
[4]Sabbah DA, Hajjo R, Sweidan K. Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors. Curr Top Med Chem 2020; 20:815–834. doi: 10.2174/1568026620666200303123102.
[5]Shah MA, Bang YJ, Lordick F, Alsina M, Chen M, Hack SP, et al. Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial. JAMA Oncol 2017;3:620–627. doi: 10.1001/jamaoncol.2016.5580.
[6]Dixelius J, Makinen T, Wirzenius M, Karkkainen MJ, Wernstedt C, Alitalo K, et al. Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-3) heterodimerization with VEGFR-2 in primary lymphatic endothelial cells regulates tyrosine phos phorylation sites. J Biol Chem 2003;278:40973–40979. doi: 10.1074/jbc.M304499200.
[7]Zhou Y, Zhu X, Cui H, Shi J, Yuan G, Shi S, et al. The Role of the VEGF Family in Coronary Heart Disease. Front Cardiovasc Med 2021;8:738325. doi: 10.3389/fcvm.2021.738325.
(0 摘要 Views, 0 PDF Downloads)
Refbacks
- 当前没有refback。